Received Jul 17, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (ENGERIX-B) | GLAXOSMITHKLINE BIOLOGICALS | 3 | 47XP4 | — |
Engerix-B pediatric dose was administered to an adult; Engerix-B pediatric dose was administered to an adult; This non-serious case was reported by a nurse via call center representative and described the occurrence of adult use of a child product in a 37-year-old female patient who received HBV (Engerix B) (batch number 47XP4, expiry date 17-JUL-2027) for prophylaxis. On 10-JUL-2025, the patient received the 3rd dose of Engerix B. On 10-JUL-2025, an unknown time after receiving Engerix B, the patient experienced adult use of a child product (Verbatim: Engerix-B pediatric dose was administered to an adult) and underdose (Verbatim: Engerix-B pediatric dose was administered to an adult). The outcome of the adult use of a child product and underdose were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 11-JUL-2025 The nurse reported that the administration of a pediatric dose of Engerix-B to an adult patient, which led to adult use of a child product and underdose It was third dose in the Engerix-B series and nurse called to get guidance on how to proceed. The reporter asked if an Engerix-B pediatric dose was administered to an adult, was that less effective and could it be combined with an adult dose The Vaccine Administration Facility is the same as Primary Reporter.